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Inorganic arsenic is an environmental pollu-
tant. Arsenic exposure in humans comes
mainly from consumption of drinking water
contaminated with inorganic arsenic [National
Research Council (NRC) 1999], but elevated
exposure can occur from burning of coal con-
taining high levels of inorganic arsenic (Liu
et al. 2002). Epidemiologic studies have
demonstrated that chronic arsenic exposure
causes tumors of the skin, urinary bladder,
lung, liver, prostate, kidney, and possibly other
sites [International Agency for Research on
Cancer (IARC) 1987; Morales et al. 2000;
NRC 1999]. Until recently, inorganic arsenic
was considered a “paradoxical” human car-
cinogen because of strong human evidence but
limited evidence for animal carcinogenesis
(IARC 1987; Waalkes et al. 2004a, 2004b).
Indeed, negative results had been obtained for
inorganic arsenic carcinogenesis in mice, rats,
hamsters, rabbits, dogs, and monkeys (IARC
1987; Kitchin 2001). Recently, important
advances have been made in the development
of rodent models of inorganic arsenic carcino-
genesis. These include skin cancer models in
which inorganic arsenic acts as a co-promoter
with 12-O-tetradecanoyl phorbol-13-acetate in
Tg.AC mice (Germolec et al. 1998), or as a 
co-carcinogen with ultraviolet irradiation in
hairless mice (Rossman et al. 2001). In addi-
tion, our group has developed a transplacental
model in which short-term exposure to in-
organic arsenic in utero produces a variety of
internal tumors in the offspring when mice
reach adulthood (Waalkes et al. 2003, 2004b).
These tumors include cancers of the liver,
lung, ovary, and adrenal induced in adulthood
by transplacental exposure to arsenic (Waalkes
et al. 2003, 2004b).
The brief period of exposure (10 days) to
inorganic arsenic, which was sufﬁcient for it to
be a complete transplacental carcinogen in
mice, is not only alarming but points to a
clear period of high sensitivity to the metal-
loid. Indeed, gestation is a period of high
sensitivity to chemical carcinogenesis in gen-
eral in both rodents and probably humans
(Anderson et al. 2000). Inorganic arsenic can
readily cross the placenta and enter the fetal sys-
tem (Chattopadhyay et al. 2002; Concha et al.
1998; NRC 1999). Thus, in human popula-
tions exposed to inorganic arsenic, it is reason-
able to assume that exposure during gestation
does occur, and that the carcinogenesis
sensitivity observed in rodents may predict
similar effects in humans.
Hepatocellular carcinoma (HCC) has
been identiﬁed as a tumor type associated with
arsenic exposure in humans (Centeno et al.
2002; Chen and Ahsan 2004; Chen et al.
1997; Zhou et al. 2002). HCC and non-
alcoholic liver cirrhosis and ascites are leading
causes of mortality in the arsenic endemic area
of Guizhou, China (Liu et al. 2002; Zhou
et al. 2002). Also, hepatomegaly and liver dis-
eases are commonly associated with arsenic
exposure through the drinking water in West
Bengal, India (Santra et al. 2000). In accord
with human data, transplacental exposure to
inorganic arsenic in mice induced a marked,
dose-related increase in HCC formation in
male offspring in both an initial (Waalkes et
al. 2003) and a subsequent followup study
(Waalkes et al. 2004a, 2004b). In utero arsenic
exposure also caused a variety of hepatic genes
to be aberrantly expressed, including genes
probably critical to the carcinogenic process,
as evidenced by analysis of liver samples taken
at autopsy during the initial transplacental
study with sodium arsenite (Liu et al. 2004;
Waalkes et al. 2004a). This initial genomic
analysis was limited to individual genes of
interest (Waalkes et al. 2004a) or to a limited
number of genes (588) in a custom array (Liu
et al. 2004). 
Our second transplacental arsenic carcino-
genesis study in mice (Waalkes et al. 2004b)
conﬁrmed the hepatocarcinogenic potential of
gestational arsenic exposure seen in the initial
study (Waalkes et al. 2003). It also provided a
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Our previous work has shown that exposure to inorganic arsenic in utero produces hepatocellular
carcinoma (HCC) in adult male mice. To explore further the molecular mechanisms of transplacen-
tal arsenic hepatocarcinogenesis, we conducted a second arsenic transplacental carcinogenesis study
and used a genomewide microarray to proﬁle arsenic-induced aberrant gene expression more exten-
sively. Brieﬂy, pregnant C3H mice were given drinking water containing 85 ppm arsenic as sodium
arsenite or unaltered water from days 8 to 18 of gestation. The incidence of HCC in adult male off-
spring was increased 4-fold and tumor multiplicity 3-fold after transplacental arsenic exposure.
Samples of normal liver and liver tumors were taken at autopsy for genomic analysis. Arsenic expo-
sure in utero resulted in significant alterations (p < 0.001) in the expression of 2,010 genes in
arsenic-exposed liver samples and in the expression of 2,540 genes in arsenic-induced HCC.
Ingenuity Pathway Analysis revealed that signiﬁcant alterations in gene expression occurred in a
number of biological networks, and Myc plays a critical role in one of the primary networks. Real-
time reverse transcriptase–polymerase chain reaction and Western blot analysis of selected genes/
proteins showed > 90% concordance. Arsenic-altered gene expression included activation of onco-
genes and HCC biomarkers, and increased expression of cell proliferation–related genes, stress pro-
teins, and insulin-like growth factors and genes involved in cell–cell communications. Liver
feminization was evidenced by increased expression of estrogen-linked genes and altered expression
of genes that encode gender-related metabolic enzymes. These novel ﬁndings are in agreement with
the biology and histology of arsenic-induced HCC, thereby indicating that multiple genetic events
are associated with transplacental arsenic hepatocarcinogenesis. Key words: Agilent mouse oligo 22K
microarray, arsenic, hepatocellular carcinoma, real-time RT-PCR, transplacental exposure, Western
blotting. Environ Health Perspect 114:404–411 (2006). doi:10.1289/ehp.8534 available via
http://dx.doi.org/ [Online 6 October 2005]unique opportunity to perform a genomewide
analysis through the National Center for
Toxicogenomics using the Agilent 22K chip
arrays. Changes in expression of speciﬁc genes
of interest were conﬁrmed by real-time reverse
transcriptase–polymerase chain reaction
(RT-PCR) and Western blot analysis. This
study confirmed and extended our initial
observations, but it also revealed a number of
novel pathways and gene expression alterations
potentially associated with hepatocarcinogene-
sis induced by transplacental arsenic exposure.
Materials and Methods
Chemicals. Sodium arsenite (NaAsO2) was
obtained from Sigma Chemical Co. (St. Louis,
MO) and dissolved in the drinking water at
85 mg arsenic/L (85 ppm). The Agilent 22K
mouse oligo array was obtained from Agilent
Technologies (Palo Alto, CA). Monoclonal
antibodies against α-fetoprotein (sc-8399),
K-ras (sc-30), c-myc (sc-42), estrogen receptor
(ER)-α (sc-8002), β-actin (sc-1616) and poly-
clonal antibodies against cyclin D1 (sc-753),
cdk4 (sc-601), and endothelial growth factor
receptor (EGFR, sc-03) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA).
Monoclonal antibodies against proliferating
cell nuclear antigen (PCNA, 610664), cyto-
keratin 5/8 (550505), and plasminogen
activator inhibitor-1 (PAI-1, 612024) were
purchased from BD Biosciences (San Jose,
CA). All other chemicals were commercially
available and of reagent grade. 
Animal treatment and sample collection.
We conducted the present study using liver
tumors and nontumorous normal liver samples
collected in the second of a series of transpla-
cental arsenic carcinogenesis studies in mice for
which pathological results have already been
reported (Waalkes et al. 2004b). In this study
timed pregnant C3H mice were given drinking
water ad libitum containing 85 ppm arsenic as
sodium arsenite or unaltered water from days
8–18 of gestation. Offspring were weaned at
4 weeks, then randomly placed into separate
groups (n = 25 from 10 dams/group) according
to maternal exposure level and observed for up
to 104 weeks. Animal care was provided in
accordance with the Guide on the Care and Use
of Animals (Institute of Laboratory Animal
Resources 1996), and the Institutional Animal
Care and Use Committee approved the study
proposal. Animals used in this study were
treated humanely and with regard for the allevi-
ation of suffering. Samples of large tumors, later
conﬁrmed as HCC, and normal surrounding
liver tissues were taken at autopsy, snap frozen
in liquid nitrogen, and compared with normal
liver samples from contemporaneous controls.
A total of 17 samples from male mice were ana-
lyzed, including 5 inorganic arsenic–induced
HCC samples (designated As-HCC), 5 samples
of surrounding nontumorous, normal liver
tissues from arsenic-treated mice (As-Normal),
and 7 samples of age-matched control mouse
liver (Control). 
Microarray analysis. We isolated total
RNA from liver samples with TRIzol agent
(Invitrogen, Carlsbad, CA), followed by puriﬁ-
cation and DNase-I digestion with RNeasy
columns (Qiagen, Valencia, CA). We evaluated
the quality of the RNA using an Agilent 2100
Bioanalyzer (Agilent Technologies). Total RNA
was amplified using the Agilent Low RNA
Input Fluorescent Linear Amplification Kit
protocol. Starting with 500 ng of total RNA,
cyanine (Cy)3- or Cy5-labeled cRNA was
produced according to the manufacturer’s
protocol. For each two-color comparison,
750 ng each of Cy3- and Cy5-labeled cRNA
was mixed and fragmented using the Agilent
In Situ Hybridization Kit protocol (Agilent
Technologies). We performed hybridizations
on Agilent mouse 22K oligo assay for 17 hr in a
rotating hybridization oven using the Agilent
60-mer oligo microarray processing protocol.
Slides were washed as indicated in this protocol
and then scanned with an Agilent Scanner.
Data were obtained using the Agilent Feature
Extraction software (version 7.5), employing
defaults for all parameters. Two hybridizations
with fluor reversals were performed for each
RNA sample from each group.
Rosetta Resolver. Images and GEML (gene
expression markup language) files, including
error and p-values, were exported from the
Agilent Feature Extraction software and
deposited into the Rosetta Resolver system
(version 4.0, build 4.0.1.0.7.RSPLIT)
(Rosetta Biosoftware, Kirkland, WA). We
combined the resultant ratio proﬁles. Intensity
plots were generated for each ratio experiment,
and genes were considered “signature genes” if
the p-value was < 0.001.
Ingenuity Pathways Analysis. We further
analyzed the signature genes with Ingenuity
Pathways Analysis (Ingenuity Systems,
Redwood City, CA; http://www.ingenuity.
com), a web-delivered application that enables
biologists to discover, visualize, and explore
relevant networks significant to their experi-
mental results, such as gene expression array
data sets. A data set containing gene identiﬁers
and their corresponding expression values such
as fold-changes and p-values was uploaded as a
tab-delimited text ﬁle. Each gene identiﬁer was
mapped to its corresponding gene object in the
Ingenuity Pathways Knowledge Base. A fold
change cutoff of 1.5-fold and p < 0.001 was set
to identify genes whose expression was differ-
entially regulated. These genes, called “focus
genes,” were then used as the starting point for
generating biological networks. To start build-
ing networks, the application queries the
Ingenuity Pathways Knowledge Base for inter-
actions between focus genes and all other gene
objects stored in the knowledge base, then
generates a set of networks with a network size
of approximately 35 genes or proteins.
Ingenuity Pathways Analysis then computes a
score for each network according to the ﬁt of
the user’s set of signiﬁcant genes. The score is
derived from a p-value and indicates the likeli-
hood of the focus genes in a network being
found together because of random chance. A
score of 2 indicates a 1 in 100 change that the
focus genes are together in a network because
of random chance. Therefore, scores of 2 or
higher have at least a 99% conﬁdence level of
not being generated by random chance alone.
Biological functions are then calculated and
assigned to each network.
Real-time RT-PCR analysis. We used
real-time RT-PCR analysis to quantify the
levels of expression of the selected genes (Liu
et al. 2004). The forward and reverse primers
for selected genes were designed using ABI
Primer Express software (Applied Biosystems,
Foster City, CA). Total RNA was reverse
transcribed with MuLV reverse transcriptase
and oligo-dT primers, then subjected to real-
time PCR analysis using SYBR green PCR
master mix (Applied Biosystems, Cheshire,
UK). The relative differences in expression
between groups were determined using cycle
time (Ct) values as follows: The Ct values of
the genes of interest were first normalized
with β-actin of the same sample; then the
relative differences between control and treat-
ment groups were calculated and expressed as
relative increases, setting the control as 100%.
Assuming the Ct value reﬂects the initial start-
ing copy and there is 100% efﬁciency, a dif-
ference of one cycle is equivalent to a 2-fold
difference in starting copy.
Western blot analysis. Tissues were homog-
enized (1:20, w:v) in PER-Tissue Protein
Extraction buffer (Pierce, Rockford, IL) con-
taining freshly added protease inhibitor cock-
tail (Calbiochem, La Jolla, CA) and 100 µM
phenylmethylsulfonyl ﬂuoride. Cytosols were
prepared by centrifugation at 15,000×g for
10 min at 4°C. Protein concentrations were
determined using the dye-binding assay
(Bio-Rad, Hercules, CA). Total protein
(30 µg) was subjected to electrophoresis on
NuPAGE Bis-Tris gels (4–12%) (Invitrogen,
San Diego, CA), followed by electrophoretic
transfer to nitrocellulose membranes at 30 V
for 1 hr. Membranes were blocked in 5% dried
milk in TBST (15 mM Tris–HCl, pH 7.4,
150 mM NaCl, and 0.05% Tween 20) for
2 hr, followed by incubation with the primary
antibody (1:200 to 1:1,000) in Blotto (Pierce,
Rockford, IL) overnight at 4°C. After washes
with TBST, the membranes were incubated in
horse radish peroxidase–conjugated secondary
antibody (1:4,000 to 1:10,000) for 1 hr and
washed with TBST 3 times. Immunoblots
were visualized using SuperSignal chemilumi-
nescent substrate (Pierce, Rockford, IL). 
Gene expression in As carcinogenesis
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cross-hybridized samples with Cy3 and Cy5.
For Ingenuity Pathways Analysis, we used a
Fisher’s exact test to calculate a p-value to
determine the probability that the biological
function assigned to that network could be
explained by chance alone. For real-time
RT-PCR analysis, means and SEM of indi-
vidual samples (n = 5–7) were calculated. For
the comparisons of gene expression between
two groups, Student’s t-test was performed.
For comparisons among three or more
groups, data were analyzed using analysis of
variance, followed by Duncan’s multiple
range test. The level of signiﬁcance was set at
p < 0.05 in all cases.
Results
Microarray analysis of aberrantly expressed
genes. The hepatocarcinogenic effects of in-
organic arsenic have been veriﬁed in a study in
Liu et al.
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Table 1. Real-time RT-PCR and microarray analysis of liver samples from adult male C3H mice exposed to arsenic in utero.
Control As-Normal As-HCC
Gene categoriesa Accession no.a (PCR) PCR Array-fold PCR Array-fold
Oncogenes and HCC-related genes
alpha-fetoprotein V00743 1.0 ± 0.2 2.3 ± 0.5 NA 19.1 ± 5.4* NA
c-myc X01023 1.0 ± 0.2 2.2 ± 0.5 1.67* 3.1 ± 0.5* 2.36*
c-met Y00671 1.0 ± 0.2 2.4 ± 0.6 1.03 3.4 ± 0.8* 1.26*
K-ras U49448 1.0 ± 0.2 1.4 ± 0.4 1.41 2.5 ± 0.6* 1.54*
PAI-1, plasminogen activator inhibitor-1 M33960 1.0 ± 0.3 2.7 ± 0.9 NA 9.2 ± 2.9* NA
Cytokeratin-8 X12789 1.0 ± 0.2 1.6 ± 0.2 NA 6.0 ± 1.3* NA
Cytokeratin-18 M11686 1.0 ± 0.3 1.3 ± 0.3 1.04 2.9 ± 0.4* 2.34*
Cytokeratin-19 NM_008471 1.0 ± 0.4 12.1 ± 4.7* 1.53* 11.1± 5.4* 1.24
BRCA1 U31625 1.0 ± 0.3 0.7 ± 0.1 1.08 0.4 ± 0.1* 0.81*
BRCA2 U65594 1.0 ± 0.1 0.8 ± 0.1 NA 0.7 ± 0.1* NA
Npn3, neoplastic progression protein-3 Z31362 1.0 ± 0.4 1.0 ± 0.3 1.05 3.1 ± 0.8* 2.41*
Cell cycle regulators and IGFs
Cyclin D1 M64403 1.0 ± 0.2 4.8 ± 1.0* 1.62* 5.1 ± 0.9* 1.51*
Cyclin E X75888 1.0 ± 0.1 4.4 ± 1.5* 1.19* 5.2 ± 1.3* 1.31*
Cdk2na NM_009877 1.0 ± 0.2 7.1 ± 1.9* 1.01 13.9 ± 3.8* 1.20
Cdk2nb AF_059567 1.0 ± 0.3 2.3 ± 0.6 NA 6.3 ± 1.8* NA
Cdk4 L01640 1.0 ± 0.3 2.5 ± 0.5 1.53* 4.4 ± 0.2* 1.76*
PCNA X53068 1.0 ± 0.1 2.5 ± 0.8 1.73* 2.6 ± 0.5* 1.76*
P16 U79632 1.0 ± 0.3 0.6 ± 0.2 0.85 0.6 ± 0.1* 0.83*
IGF-1 X04480 1.0 ± 0.1 0.7 ± 0.1 0.65* 0.6 ± 0.1* 0.53*
IGF-2 M14951 1.0 ± 0.2 3.3 ± 2.1 3.77* 4.4 ± 2.0* 4.21*
IGFBP1 X81579 1.0 ± 0.3 2.7 ± 0.5* 1.15 9.1 ± 3.2* 4.18*
IGFBP3 X81581 1.0 ± 0.4 2.9 ± 0.8* 0.88 2.9 ± 0.8* 0.88
IGFBP5 X81583 1.0 ± 0.2 4.6 ± 1.5* 0.94 2.4 ± 0.9* 0.91
Stress-related genes
GST-alpha4 AK008490 1.0 ± 0.4 2.5 ± 0.6* 1.94* 2.5 ± 0.6* 2.16*
GST-mu J03953 1.0 ± 0.4 3.5 ± 0.8* 1.54* 4.8 ± 1.1* 1.26*
GST-theta X98055 1.0 ± 0.5 3.5 ± 0.8* 1.14 3.1 ± 0.9* 1.31*
GST-pi NM_013541 1.0 ± 0.4 2.5 ± 0.6* 2.23 2.5 ± 0.6* 1.11
EGR1, early response protein-1 M20157 1.0 ± 0.5 3.5 ± 0.8* 1.24* 3.1 ± 0.9* 5.20*
SOD-1 M01143 1.0 ± 0.4 2.5 ± 0.6* NA 2.5 ± 0.6* NA
Ceruloplasmin U49430 1.0 ± 0.1 4.1 ± 1.0* 1.02 4.3 ± 1.5* 1.14*
HO-1, heme oxygenase-1 M33203 1.0 ± 0.1 1.0 ± 0.2 1.51* 0.9 ± 0.2   1.23*
MT-1 BC027262 1.0 ± 0.2 0.6 ± 0.3 0.50* 0.5 ± 0.1* 0.59*
Genes for metabolic enzymes
CYP2A4 J03549 1.0 ± 0.1 3.1 ± 0.9* 1.05 25.3 ± 8.7* 2.51*
CYP2F2 M77497 1.0 ± 0.2 1.0 ± 0.2 1.12 0.5 ± 0.2* 0.68*
CYP2B9 M21855 1.0 ± 0.4 1.9 ± 0.6 0.85 2.6 ± 1.1* 0.43
CYP2D9 M27168 1.0 ± 0.4 5.3 ± 1.0* 1.15* 4.7 ± 1.2* 1.06
CYP3A41 NM_017396 1.0 ± 0.5 0.4 ± 0.2 0.55* 0.4 ± 0.1* 0.57*
CYP7B1 U36993 1.0 ± 0.3 0.7 ± 0.3 0.82* 0.5 ± 0.1* 0.39*
Akr1c18, aldo-keto reductase 1c18 NM_134066 1.0 ± 0.5 2.5 ± 0.8 1.39 61.7 ± 27.8* 15.3*
HSD17 β7 NM_010476 1.0 ± 1.4 3.1 ± 0.4* 0.92 2.8 ± 0.4 0.99
TFF3, trefoil factor 3 NM_011575 1.0 ± 0.1 3.2 ± 1.0* 5.82* 6.3 ± 1.8* 10.9*
Cyr61, cysteine-rich protein 61 NM_010516 1.0 ± 1.0 1.7 ± 0.3 0.85 4.9 ± 1.7* 1.17
Lp1, lipoprotein lipase NM_008509 1.0 ± 0.1 12.1 ± 5.1* 4.61* 33.2 ± 13.1* 9.21*
Cte1, cytosolic acyl-CoA thioestase1 NM_012006 1.0 ± 0.2 2.7 ± 0.8 1.29* 4.8 ± 1.8* 2.18*
Pmsc3, proteasome 26S subunit, ATPase3 D49686 1.0 ± 1.1 2.6 ± 0.4 1.62* 4.1 ± 1.1* 1.61*
BHMT, homocysteine methyltransferase AF033381 1.0 ± 0.1 0.7 ± 0.1 0.84* 0.6 ± 0.1* 0.63*
Saa3, serum amyloid 3 NM_011315 1.0 ± 0.3 2.2 ± 0.7 0.23* 0.3 ± 0.1* 0.05*
SULT-X2 AF026075 1.0 ± 0.1 0.1 ± 0.0* 0.21* 0.0 ± 0.0* 0.16*
Cell communication and signal transduction
Annexin A2 M14044 1.0 ± 0.3 9.0 ± 2.9* 2.30* 48.5 ± 16.9* 8.64*
Nid1, nidogen 1 NM_010917 1.0 ± 0.2 3.1 ± 1.1 2.60* 56.2 ± 9.8* 10.5*
β-catenin NM_007614 1.0 ± 0.3 4.2 ± 0.8* 2.01* 6.9 ± 2.4* 2.03*
E-cadherin NM_009864 1.0 ± 0.3 4.4 ± 1.5* 1.24* 11.2 ± 4.5* 4.34*
Ptgs-2, prostaglandin-endoperoxide synthase 2 NM_011198 1.0 ± 0.4 2.6 ± 1.0 1.12 5.6 ± 2.5* 1.18
Rhou, ras homolog gene family U NM_133955 1.0 ± 0.2 3.1 ± 0.8* NA 3.9 ± 1.0* NA
CTGF, ﬁbronectin NM_022266 1.0 ± 0.3 2.7 ± 0.6 2.50* 3.7 ± 0.8* 1.90*
Prlr, prolactin receptor NM_011169 1.0 ± 0.4 0.4 ± 0.2 0.37* 0.4 ± 0.1* 0.23*
Egfr, epidermal growth factor receptor NM_007912 1.0 ± 0.2 1.1 ± 0.2 0.71* 0.5 ± 0.1* 0.63*
NA, same gene access clone is not available. Data are mean ± SEM of 5–7 individual animals. 
aGene names, symbols, and accession numbers are from GenBank (http://www.ncbi.nih.gov/GenBank/). *Signiﬁcantly different from controls p < 0.05. which HCC developed in high incidence in
male mice after in utero exposure (Waalkes et al.
2004b). Thus, total RNA was isolated from
samples of control mouse liver, arsenic-exposed
nontumorous normal liver, and arsenic-induced
HCC taken at autopsy, and subjected to
microarray analysis. Under the criteria of p <
0.001 by the Rosetta Resolver (version 4.0) sys-
tem, the expression of 2,010 genes was signiﬁ-
cantly altered in arsenic-exposed normal liver
samples compared with control, and 2,540
genes were altered in arsenic-induced HCC.
The clustering analysis of these gene alterations
clearly showed they generally occur in the same
direction (increase or decrease) but are much
more pronounced in arsenic-induced tumors
than normal surrounding tissue from arsenic
exposed mice (Table 1, Figure 1). Examples of
a cluster showing increased genes (shown in
red) and an example of a gene cluster showing
decreased genes (green) are shown in Figure 1.
Generally, gene alterations seen in the present
study are largely consistent with the previous,
more limited gene analysis (Liu et al. 2004) of
our ﬁrst transplacental arsenic carcinogenesis
study (Waalkes et al. 2003). The significant
gene expression alterations (p < 0.001 and
1.5-fold cutoff) were further selected for
Ingenuity Pathway Analysis. 
Ingenuity Pathways Analysis. To further
analyze the biological signiﬁcance of these alter-
ations in gene expression, we used the Ingenuity
Pathways Analysis; an example of the highest
score in the analysis from arsenic-induced
tumors (Figure 2) is depicted. The intensity of
the node color indicates the degree of increased
(red) or decreased (green) expression in arsenic-
induced HCC. Biological functions were
assigned to each gene network by using the
ﬁndings extracted from the published scientiﬁc
literature and stored in the Ingenuity Pathways
Knowledge Base (http://www.ingenuity.com/
products/PathwaysKnowledge.pdf) and are
ranked according to the signiﬁcance of that bio-
logical function to the network. The activation
of c-myc oncogene and its central role in related
pathway alterations are consistent with the pub-
lished literature on arsenic (Chen et al. 2001b),
and could be a major component of its hepato-
carcinogenic potential. 
Real-time RT-PCR analysis of aberrantly
expressed genes. To confirm and extend
microarray results, we performed real-time RT–
PCR analysis of selected genes using individual
samples from control mouse liver, arsenic-
exposed nontumorous livers, and arsenic-
induced HCC. Generally, real-time RT-PCR
conﬁrmed microarray results with > 90% con-
cordance but tended to show more pronounced
changes than microarray analysis (Table 1). For
HCC biomarkers, alpha-fetoprotein (AFP,
19-fold), plasminogen activator inhibitor-1
(PAI-1, 9-fold), cytokeratin 8 (6-fold), cyto-
keratin 18 (3-fold) and cytokeratin 19 (11-fold),
were dramatically increased in arsenic-induced
HCC. The oncogenes c-myc, c-met, k-ras and
the neoplastic progression protein-3 (Npn3)
were also increased 2- to 3-fold in arsenic-
induced HCC and nontumorous, normal liver
from arsenic exposed mice, while the tumor
suppressors BRCA1 and BRCA2 decreased
30–50%. 
The positive cell cycle regulators cyclin D1
(5-fold), cyclin E (5-fold), cdk2na (14-fold),
cdk2nb (6-fold), cdk4 (4-fold), and PCNA
(3-fold) were increased as a result of arsenic
exposure, while the cell cycle negative regula-
tor p16 decreased 40%. The expression of
insulin-like growth factor-1 (IGF-1, 60% of
control) was decreased, while the expression of
IGF-2 was increased 4-fold. The IGF-binding
proteins (IGFBP1, 9-fold), IGFBP3 (3-fold),
and IGFBP5 (2.4-fold) were all increased to
some extent.
Arsenic produces oxidative stress within
cells as a possible mechanism of its toxicity
(Liu et al. 2001a). Stress-related genes, includ-
ing various glutathione S-transferases (GST-
alpha, GST-mu, GST-pi, and GST-theta) and
early growth response protein 1 (EGR1),
increased 2.5- to 4.5-fold. In addition, Cu,Zn-
superoxide dismutase (SOD1) and cerulo-
plasmin (Cu-binding protein) were also
increased approximately 3-fold by arsenic. In
comparison, no major changes occurred in the
expression of heme oxygenase-1 (HO-1), a
biomarker for arsenic-induced oxidative stress
(NRC 1999), and the expression of metallo-
thionein-1 (MT-1) actually decreased 50%.
A feminized pattern of metabolic enzymes
has been noted in male livers of mice bearing
arsenic-induced HCC after in utero exposure
(Waalkes et al. 2004a). Marked elevation in
expression of the female predominant
cytochrome P450 (CYP)2A4 (25-fold), and sig-
niﬁcant increases (2- to 3-fold) of female domi-
nant CYP2B9 (2.6-fold) and CYP2D9 were
evident. In contrast, expression of the male
dominant CYP7B1, CYP2F2, and CYP41 were
all decreased by approximately 50% by arsenic
exposure. Further evidence for feminization
includes increased expression of aldo-keto
reductase 1c18 (Akr1c18) and hydroxysteroid
17β dehydrogenase 7 (HSD 17β7), as well as
ER-α linked overexpression of trefoil factor 3
(TFF3) and cysteine-rich protein 61 (Cyr61).
No apparent changes occurred for CYP2C39,
CYP2E1, CYP2J5, CYP3A25, and CYP4A14
(data not shown). Interestingly, the enzymes
for lipid metabolism such as lipoprotein lipase
(Lpl, 33-fold), cytosolic acyl-CoA thioesterase
(Cte1, 5-fold), and proteasome 26S subunit
ATPase-3 (Pmsc3, 4-fold) were increased.
Conversely, betaine homocysteine methyl-
transferase (BHMT, 60% of control), serum
amyloid 3 (Saa3, 30% of control), and
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Figure 1. Altered gene expression in adult male mice exposed to arsenic in utero. The signiﬁcantly altered
genes under criteria of > 1.5-fold difference and p < 0.001 were clustered for comparison. Arsenic-
exposed normal liver samples and arsenic-induced liver tumors are compared to control livers. Increased
gene expression is shown in red, and decreased gene expression is shown in green. Gene symbols and
accession numbers are from GenBank (http://www.ncbi.nih.gov/GenBank/).sulfotransferase-related protein 2 (SULT-X2,
1% of control) were decreased.
For cell–cell interaction genes and genes
involved in signal transduction, marked
increases occurred in annexin A2 (48-fold),
nidogen 1 (50-fold), E-cadherin (11-fold),
and β-catenin (7-fold) in arsenic-induced
HCC. Moderate increases in the ras homolog
gene family U (Rhou, 4-fold), in ﬁbronection
(CTGF, 4-fold), and in prostaglandin-
endoperoxide synthase 2 (Ptgs-2, 5.5-fold)
were also evident. In contrast, the prolactin
receptor (Prlr, 40% of control) and the epi-
dermal growth factor receptor (Egfr, 40% of
control) were decreased as a result of in utero
exposure to inorganic arsenic.
Western blot analysis of aberrantly
expressed proteins. We also performed
Western blot analysis on selected gene prod-
ucts (Figure 3). Western blot analysis largely
confirmed the gene expression results and
clearly showed the increases in the expression
of potential oncogenes AFP, K-ras, and c-Myc
in both arsenic-exposed nontumorous livers
and arsenic-induced HCC. The cell cycle
regulators, such as ER-α, the ER-α linked
cyclin D1, cyclin-dependent kinase 4 (cdk4),
and proliferating cell nuclear antigen (PCNA),
all followed this pattern of high in tumor tis-
sues, intermediate in tumor-surrounding livers
and low in control liver. The HCC biomark-
ers cytokeratin 8 and plasminogen activator
inhibitor 1 (PAI-1) were all significantly
increased in arsenic-induced HCC, and also
higher in arsenic-exposed tumor-surrounding
tissues. Endothelial growth factor receptor
(EGFR) was down-regulated in arsenic-
induced HCC. The expression of β-actin was
consistent among lanes.
Discussion
Our most recent transplacental arsenic carcino-
genesis study (Waalkes et al. 2004b) conﬁrmed
the hepatocarcinogenic potential of arsenic in
adult male mice after transplacental exposure
(Waalkes et al. 2003), and it also provided an
opportunity for a genomewide gene expression
analysis. The 22K mouse chip array revealed
several novel pathways and gene expression
alterations associated with arsenic-induced
HCC and in arsenic-exposed nontumorous
normal liver samples, which were not detected
in previous limited gene expression analysis.
Liver is a major target organ for arsenic in
rodents and in humans (Liu et al. 2000; 2002;
Santra et al. 2000). In other studies, HCC
formation has been associated with arsenic
exposure in humans (Centeno et al. 2002;
Chen et al. 1997; Chiu et al. 2004; Zhou et al.
2002). Therefore, the present gene profiling
study in mice of a concordant human target
tissue is noteworthy because it clearly demon-
strates that multiple genetic events occurred
during the carcinogenic process in the liver
induced by in utero exposure to arsenic. It is
reasonable to anticipate a complicated series of
genetic interactions in arsenic-induced carcino-
genesis, which this study certainly shows.
However, the present results also provide a
variety of candidate genes to investigate in
greater detail, such as with time-course experi-
ments, to deﬁne events early after transplacen-
tal arsenic exposure. Furthermore, recent
evidence indicates that early life chemical expo-
sures may aberrantly “reprogram” gene expres-
sion patterns, thus resulting in altered growth
responses and cancer later in life, as with
diethylstilbestrol and uterine cancer (Cook
et al. 2005). Consistent with this concept, the
altered gene expression patterns seen in adults
after in utero arsenic exposure could have
resulted from the early life reprogramming
during a critical stage in development. 
Clustering analysis clearly shows that the
gene changes in HCC and normal liver samples
taken from mice exposed to arsenic in utero are
Liu et al.
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Figure 2. The Ingenuity Pathways Analysis of gene expression changes (detailed in “Material and Methods”).
The network number 1 from arsenic-induced HCC and control liver samples is depicted. The central role of
MYC activation in transplacental arsenic carcinogenesis is illustrated. Red indicates increases in gene














Figure 3. Western blot analysis of selected proteins
in control mouse livers (Cont), arsenic-exposed non-
tumorous livers [As-Normal (AsN)], and arsenic-
induced liver tumors (As-T ) in adult male mice.
Lanes 1–3 show control liver; lanes 4–6 show arsenic
exposed nontumorous normal liver; and lanes 7–9
show arsenic-induced HCC. The apparent kDa val-
ues were AFP ≈ 75 kDa, K-ras ≈ 28 kDa, c-Myc ≈
70 kDa ER-α≈70 kDa, cyclin D1 ≈ 35 kDa, cdk4 ≈ 33
kDa, PCNA ≈ 36 kDa, cytokeratin 8 ≈ 54 kDa. PAI-1 ≈
47 kDa, EGFR ≈200 kDa, and β-actin ≈43 kDa.for the most part directionally consistent but
with quantitatively greater changes in the
arsenic-induced tumors. The gene expression
alterations associated with arsenic hepato-
carcinogenesis have an important impact on as
many as 50 biological networks shown by
Ingenuity Pathways Analysis to be signiﬁcantly
altered or interrupted. The observation that a
large number of graded gene expression changes
occurred both in nontumorous and in tumor-
ous liver samples from adults exposed to arsenic
in utero is important because it implies that
complex changes initiated during gestation
appear to have persisted into adulthood. Some
of those alterations are very likely relevant to the
carcinogenic process. The complex nature of
this arsenic-induced response argues against
mutational activation of a few key pathways
and perhaps points toward other mechanisms
for persistent gene expression change. For
example, the central network role for c-Myc
seen in the present study is consistent with
c-myc activation in arsenic-transformed rat liver
cells (Chen et al. 2001b), in hamster embryo
cells (Takahashi et al. 2002), and in murine
ﬁbroblasts (Trouba et al. 2000). This central
network role also agrees with that suggested by
results from arsenic-induced skin tumors
(Germolec et al. 1998) and from HCC induced
by in utero arsenic exposure (Liu et al. 2004).
Overexpression of c-myc may be caused by
arsenic-induced DNA hypomethylation of the
c-myc promoter region (Takahashi et al. 2002).
The activation of c-myc oncogene can in turn
result in many other gene expression changes.
For example, the increased expression of the
N-myc downstream regulated gene 1
(NDRG1) is associated with HCC formation.
The increased expression of stearoyl-CoA
desaturase-1 (SCD-1) plays a key role in
lipogenic gene expression and in metabolic
syndrome, which coincides with marked eleva-
tions of lipoprotein lipase (Lpl, 33-fold) and
cytosolic acyl-CoA thioesterase-1 (Cte1,
5-fold) in arsenic-induced HCC. This
increased expression could also be important
for arsenic-induced hepatic steatosis (Chen
et al. 2004). Interestingly, in this network, the
increase in C-myc is associated with a decrease
in metallothionein-1 expression (MT-1),
which was confirmed by RT-PCR analysis.
MT is an adaptive protein in response to
arsenic exposure (Liu et al. 2000). The decrease
in MT could be a marker for liver tumor pro-
gression because MT is poorly expressed in
both mouse and human HCC (Waalkes et al.
1996). Determining the changes that are
specific to arsenic and the changes that are
part of the potentially autonomous process of
liver oncogenesis will be a major challenge,
but the present work opens various avenues
for further study.
In addition to c-myc overexpression, the
activation of various oncogenes such as k-ras
and c-met was also evident following trans-
placental arsenic exposure, as seen with arsenic-
transformed rat liver cells (Chen et al. 2001a).
Overexpression of k-ras is also associated with
arsenic-induced malignant transformation in
human prostate epithelial cells (Benbrahim-
Tallaa et al. 2005). Ha-ras mutation and over-
expression, as in genetically altered Tg.AC
mice, is associated with arsenic-induced co-
promotion of skin tumors (Germolec et al.
1998). In a fashion similar to c-myc, DNA
hypomethylation could be responsible for ras
oncogene overexpression, and chronic arsenic
exposure in vivo appears to induce a loss of
methylation at several cytosine sites within the
promoter region of the hepatic Ha-ras gene in
mice (Okoji et al. 2002). The Ras-mediated
signal transduction molecule Rhou (ras
homolog gene family U) was also increased
3- to 4-fold in arsenic-exposed tissues in the
present study. The HCC biomarkers α-feto-
protein, plasminogen activator inhibitor 1
(PAI-1), cytokeratin 8, cytokeratin 18, and
cytokeratin 19, as well as the neoplastic pro-
gression protein-3, were all significantly
increased, consistent with HCC pathobiology
and previous ﬁndings with arsenic (Liu et al.
2004). Conversely, the tumor suppressor genes
BRCA1 and BRCA2 were decreased. BRCA1
protein interacts directly with ER-α, thereby
resulting in inhibition of estradiol-stimulated
ER-α transcriptional activity (Ma et al. 2005).
Thus, down-regulation of BRCA1 and
BRCA2 could play a role in the overexpression
of ER-α and ER-α–linked gene expression
observed in this model of arsenic carcinogene-
sis (Waalkes et al. 2004a). 
The tumors (in the liver, ovary, adrenal,
lung) and proliferative lesions (in the uterus
and oviduct) induced by in utero arsenic expo-
sure can all similarly be induced by estrogenic
carcinogens (Waalkes et al. 2003; 2004b).
Indeed, prior results demonstrated the over-
expression of ER-α with a nuclear localization
(active form) in adult male liver after in utero
arsenic exposure (Waalkes et al. 2004a; Chen
et al. 2004), a result confirmed by Western
blot analysis in the present study. This ﬁnding
leads to the hypothesis that arsenic could
somehow produce estrogenic-like effects, possi-
bly directly or indirectly through stimulation
of ER-α, thus resulting in tumor formation
(Waalkes et al. 2004a). Overexpression of
ER-α could be caused by arsenic-induced
DNA hypomethylation of the promoter region
of the ER-α gene (Chen et al. 2004; Waalkes
et al., 2004a). Such overexpression is associated
with the feminization pattern of liver meta-
bolic enzymes in male liver bearing arsenic-
induced HCC (Liu et al. 2004; Waalkes et al.
2004a). In the present study, marked elevation
of the female predominant CYP2A4, CYP2B9,
and CYP2D9 and signiﬁcant decreases in male
dominant CYP7B1, CYP2F2, and CYP41
were evident following transplacental arsenic
exposure in male offspring, consistent with this
hypothesis. The contribution of ER-α signal-
ing pathways to arsenic-induced HCC could
be multifactorial, including the increased tre-
foil factor-3 (TFF3), cyclin D1, and the CCN
family members cysteine-rich 61 (Cyr61) and
connective tissue growth factor (CTGF).
Overexpression of TFF3 is proposed to be a
critical process in hepatocarcinogenesis (Okada
et al. 2005), and overexpression of Cyr61
and CTGF is associated with recurrence and
metastasis of HCC (Zeng et al. 2004).
Estrogen-induced progression through the
G1 phase of the cell cycle is preceded by
increased expression of the G1-phase regulatory
proteins c-Myc and Cyclin D1 (Prall et al.
1998). Cyclin D1 overexpression is important
for HCC formation and is considered a hepatic
oncogene (Deane et al. 2001). Overexpression
of cyclin D1 has been reported in arsenic-
transformed cells (Chen et al. 2001b), during
arsenic-induced skin co-carcinogenicity in mice
(Rossman et al. 2001), in dimethylarsinic
acid–induced bladder proliferative lesions in
rats (Wei et al. 2002), in chronic arsenate-
exposed rats (Cui et al. 2004), and in the livers
of mice bearing HCC induced by in utero
exposure to arsenic (Liu et al. 2004). Cyclin D1
overexpression, together with other positive cell
cycle regulators such as cyclin E, cdk4, cdkn2a,
cdkn2b, and PCNA was evident in arsenic-
exposed tissues in the present study. Thus, cell
cycle dysregulation, as manifested in cyclin D1
overexpression, appears to be a consistent event
in arsenic-induced oncogenesis. In comparison,
expression of the negative cell cycle regulator
p16 was decreased, consistent with prior obser-
vations with arsenic (Chen et al. 2001a; Liu
et al. 2004). In addition to these cell cycle regu-
lators, annexin A2 was also dramatically
increased (48-fold) in arsenic-induced HCC.
Annexins belong to a family of the calcium-
dependent phospholipid binding proteins and
are substrates of receptor tyrosine kinases.
Annexin A2 overexpression is common in vari-
ous carcinomas (Emoto et al. 2001), and
annexin A2 can interact with c-Myc in increas-
ing cell proliferation (Mickleburgh et al. 2005).
Dysregulation of the IGF axis, including IGF-1
and IGF-2, and IGF binding proteins, was 
evident in our prior work (Liu et al. 2004) and
in our present studies. A decrease in IGF-1 and
an increase in IGFBP1 in arsenic-exposed livers
are similar to ﬁndings with the nongenotoxic
model carcinogens such as oxazepam and
Wyeth-14,643 (Iida et al. 2003). Dysregulation
of the IGF axis may also well contribute to
uncontrolled cell proliferation and hepato-
carcinogenesis (Scharf and Braulke 2003). 
The expression of oxidative stress-related
genes is associated with arsenic toxicity and cell
proliferation (Liu et al. 2001; Pi et al. 2003).
For example, overexpression of early growth
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induced proliferation in urinary bladder cells
(Simeonova et al. 2000) and in arsenic-induced
HCC (Liu et al. 2004). The activation of tran-
scription factor Nrf2 by arsenic and the Nrf2-
mediated overexpression of antioxidants such
as Cu,Zn superoxide dismutase (SOD1) is evi-
dent in arsenic-exposed cells (Pi et al. 2003).
Expression of SOD1 and the Cu-binding pro-
tein ceruloplasmin was increased in arsenic-
exposed liver and in arsenic-induced liver
tumors in the present work. The increases in
these acute phase proteins may have clinical
relevance because increased ceruloplasmin
(Bencko et al. 1988) and SOD1 (Lu et al.
2001) have been reported in arsenic-exposed
humans. Heme oxygenase-1, a biomarker for
acute arsenic-induced oxidative stress (Liu et al.
2001a; NRC 1999), was not significantly
altered in the present study. In comparison,
GST-alpha, GST-mu, GST-pi, and GST-theta
expressions were all increased following
in utero arsenic exposure, similar to previous
observations in chronic arsenic exposure set-
tings (Liu et al. 2000; Lu et al. 2001; Xie et al.
2004). Increased GSTs likely play a role in
conjugation and detoxication of lipid peroxides
produced by arsenic, but they also play a role
for cellular efﬂux of arsenic via MRP pumps
(Leslie et al. 2004; Liu et al. 2001b). The
increased demand for GSH utilization may
activate the use of homocysteine for GSH syn-
thesis, rather than for S-adenosylmethionine
(SAM), and, consequently, disrupt cellular
methyl homeostasis (Lu et al. 2002). In this
regard, expression of betaine-homocysteine
methyltransferase was markedly decreased, and
it is a key enzyme in SAM recycling. This dis-
ruption of SAM production may contribute to
a cellular environment conducive to errors in
DNA methylation, which can be a contribut-
ing factor to aberrant gene expression.
Both β-catenin and E-cadherins are impor-
tant cell–cell communication molecules. The
overexpression of β-catenin is linked to
cyclin D1 overexpression in HCC (Iida et al.,
2003). Furthermore, β-catenin can also affect
tumor progression by stimulating proliferation,
and overexpression is associated with a poor
prognosis for patients with HCC. E-cadherin
is a cell–cell adhesion molecule that plays a key
role in the development and maintenance of
cell polarity. Dysregulation of E-cadherin is
also associated with HCC (Calvisi et al. 2004).
Nidogen-1 acts as a bridge between the extra-
cellular matrix molecules laminin-1 and colla-
gen IV, and it participates in the assembly of
the basement membranes. In the present study,
nidogen 1 (50-fold), β-catenin (7-fold), and
E-cadherin (11-fold) were all dramatically
increased in transplacental arsenic-induced
HCC and in arsenic-exposed liver tissues.
Conversely, the prolactin receptor and EGFR
were decreased in arsenic-induced HCC,
thereby suggesting that the dysregulation of
cell–cell communications and signal transduc-
tion pathways could be another important
aspect of arsenic hepatocarcinogenesis, as has
been proposed for liver cancer in general.
In summary, we used a genomewide analy-
sis to dissect further the toxicogenomics
changes of transplacental arsenic hepatocarcino-
genesis in the mouse. These findings clearly
demonstrate that arsenic carcinogenesis in the
liver involves a complex interplay between mul-
tiple genetic events, including stimulation of
oncogene expression, liver feminization, cell
cycle dysregulation, and disruption of cell–cell
communication. This study indicates that early
life exposure to arsenic during a critical stage in
development may have resulted in aberrant
genetic reprogramming that leads to events
associated with hepatocarcinogenesis later in
life. Finally, the present results highlight the
importance of protecting pregnant women
from excessive arsenic exposure.
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